CL2014000079A1 - El compuesto n-(6-((2r,3s)-3,4-dihidroxibutan-2iloxi)-2-(4-fluorobenciltio) pirimidin-4-ilo)-3-metilacetidina-1-sulfonamida, receptor de qumiocina; forma cristalina; proceso de preparación; compuesto intermediario; composicion farmaceutica; y su uso en asma, rinitis alergica, epoc, sindrome de colon irritable, enfermedad intestinal inflamatoria, entre otras - Google Patents

El compuesto n-(6-((2r,3s)-3,4-dihidroxibutan-2iloxi)-2-(4-fluorobenciltio) pirimidin-4-ilo)-3-metilacetidina-1-sulfonamida, receptor de qumiocina; forma cristalina; proceso de preparación; compuesto intermediario; composicion farmaceutica; y su uso en asma, rinitis alergica, epoc, sindrome de colon irritable, enfermedad intestinal inflamatoria, entre otras

Info

Publication number: CL2014000079A1
Authority: CL; Chile
Prior art keywords: compound; methylacetyidine; fluorobenzylthio; epoc; dihydroxybutane
Prior art date: 2011-07-12

Application number

CL2014000079A

Other languages

English (en)

Inventor

Stephen Connolly

Mark Richard Ebden

Thomas Langer

Alan Robert Steven

Craig Robert Stewart

Paula Margart Tomlin

Andrew John Williams

Lain Alastair Stewart Walters

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-12

Filing date

2014-01-10

Publication date

2014-06-27

2014-01-10 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2014-06-27 Publication of CL2014000079A1 publication Critical patent/CL2014000079A1/es

Links

150000001875 compounds Chemical class 0.000 title 2
-1 6 - ((2r, 3s) -3,4-dihydroxybutane-2-yloxy) -2- (4-fluorobenzylthio) pyrimidin-4-yl Chemical group 0.000 title 1
102000009410 Chemokine receptor Human genes 0.000 title 1
108050000299 Chemokine receptor Proteins 0.000 title 1
208000022559 Inflammatory bowel disease Diseases 0.000 title 1
206010039085 Rhinitis allergic Diseases 0.000 title 1
201000010105 allergic rhinitis Diseases 0.000 title 1
208000006673 asthma Diseases 0.000 title 1
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 title 1
208000002551 irritable bowel syndrome Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
229940124530 sulfonamide Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/20—Free hydroxyl or mercaptan
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

CL2014000079A 2011-07-12 2014-01-10 El compuesto n-(6-((2r,3s)-3,4-dihidroxibutan-2iloxi)-2-(4-fluorobenciltio) pirimidin-4-ilo)-3-metilacetidina-1-sulfonamida, receptor de qumiocina; forma cristalina; proceso de preparación; compuesto intermediario; composicion farmaceutica; y su uso en asma, rinitis alergica, epoc, sindrome de colon irritable, enfermedad intestinal inflamatoria, entre otras CL2014000079A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161506737P	2011-07-12	2011-07-12

Publications (1)

Publication Number	Publication Date
CL2014000079A1 true CL2014000079A1 (es)	2014-06-27

Family

ID=46513787

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000079A CL2014000079A1 (es)	2011-07-12	2014-01-10	El compuesto n-(6-((2r,3s)-3,4-dihidroxibutan-2iloxi)-2-(4-fluorobenciltio) pirimidin-4-ilo)-3-metilacetidina-1-sulfonamida, receptor de qumiocina; forma cristalina; proceso de preparación; compuesto intermediario; composicion farmaceutica; y su uso en asma, rinitis alergica, epoc, sindrome de colon irritable, enfermedad intestinal inflamatoria, entre otras

Country Status (38)

Country	Link
US (3)	US8735413B2 (es)
EP (2)	EP2731945A1 (es)
JP (2)	JP6006308B2 (es)
KR (1)	KR101946664B1 (es)
CN (1)	CN103781781B (es)
AR (2)	AR087168A1 (es)
AU (2)	AU2012282316B2 (es)
BR (1)	BR112014000636B1 (es)
CA (1)	CA2841859C (es)
CL (1)	CL2014000079A1 (es)
CO (1)	CO6852072A2 (es)
CR (1)	CR20140007A (es)
CU (2)	CU24292B1 (es)
CY (1)	CY1124329T1 (es)
DK (1)	DK3255043T3 (es)
DO (1)	DOP2013000308A (es)
EA (1)	EA027821B1 (es)
EC (1)	ECSP14013130A (es)
ES (1)	ES2861927T3 (es)
HR (1)	HRP20210413T1 (es)
HU (1)	HUE053703T2 (es)
IL (1)	IL230398A (es)
LT (1)	LT3255043T (es)
MX (2)	MX342874B (es)
MY (1)	MY180039A (es)
NI (1)	NI201400002A (es)
PE (2)	PE20181069A1 (es)
PH (1)	PH12014500107A1 (es)
PL (1)	PL3255043T3 (es)
PT (1)	PT3255043T (es)
RS (1)	RS61608B1 (es)
SG (1)	SG10201605619XA (es)
SI (1)	SI3255043T1 (es)
SM (1)	SMT202100173T1 (es)
TW (2)	TWI633098B (es)
UY (1)	UY34191A (es)
WO (1)	WO2013008002A1 (es)
ZA (1)	ZA201401059B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012007748A1 (en)	2010-07-13	2012-01-19	Astrazeneca Ab	New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX342874B (es) *	2011-07-12	2016-10-17	Astrazeneca Ab	N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
EP3141235A1 (en) *	2012-12-06	2017-03-15	IP Gesellschaft für Management mbH	N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
EP3426253A4 (en) *	2016-03-11	2019-11-06	Ardea Biosciences, Inc.	CXCR-2 INHIBITORS FOR THE TREATMENT OF CRYSTALARTHROPATHIES
WO2019055509A1 (en) *	2017-09-12	2019-03-21	Ardea Biosciences, Inc.	INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS
ES2961184T3 (es)	2019-06-12	2024-03-08	Nouryon Chemicals Int Bv	Proceso para la producción de peróxidos de diacilo
ES2963357T3 (es)	2019-06-12	2024-03-26	Nouryon Chemicals Int Bv	Proceso para la producción de peróxidos de diacilo
WO2020249689A1 (en)	2019-06-12	2020-12-17	Nouryon Chemicals International B.V.	Process for the production of peroxyesters
US20220306490A1 (en) *	2019-06-12	2022-09-29	Nouryon Chemicals International B.V.	Method for isolating carboxylic acid from an aqueous side stream
ES2963382T3 (es)	2019-06-12	2024-03-26	Nouryon Chemicals Int Bv	Proceso para la producción de peróxidos de diacilo

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3457278A (en) *	1964-10-15	1969-07-22	Geigy Chem Corp	Cyclopropyl-4-sulfanilamido-pyrimidines
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
JP4471404B2 (ja)	1996-02-13	2010-06-02	アストラゼネカユーケイリミテッド	Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de)	1996-03-05	2002-01-15		4-anilinochinazolin derivate
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
FI981521A0 (fi) *	1998-07-01	1998-07-01	Orion Corp	Substituoidut beta-diketonit ja niiden käyttö
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
NZ522074A (en)	2000-05-31	2004-06-25	Astrazeneca Ab	Indole derivatives with vascular damaging activity
JP2004502766A (ja)	2000-07-07	2004-01-29	アンギオジェン・ファーマシューティカルズ・リミテッド	血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en)	2000-07-07	2002-01-31	Angiogene Pharmaceuticals Limited	Colchinol derivatives as angiogenesis inhibitors
GB0217431D0 (en)	2002-07-27	2002-09-04	Astrazeneca Ab	Novel compounds
RU2408587C2 (ru)	2004-08-24	2011-01-10	Астразенека Аб	Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов
GB0419235D0 (en) *	2004-08-28	2004-09-29	Astrazeneca Ab	Compounds
JP5237115B2 (ja) *	2006-01-19	2013-07-17	オーキッドリサーチラボラトリーズリミテッド	新規複素環類
WO2008157273A1 (en) *	2007-06-14	2008-12-24	Smithkline Beecham Corporation	Chemical compounds
KR20110031462A (ko) *	2008-07-16	2011-03-28	아스트라제네카 아베	피리미딜 술폰아미드 유도체 및 케모카인 매개 질환의 치료를 위한 그의 용도
CN102105434A (zh)	2008-07-25	2011-06-22	巴斯夫欧洲公司	3-氨基甲基-1-环己基胺及其生产方法
WO2012007748A1 (en) *	2010-07-13	2012-01-19	Astrazeneca Ab	New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX342874B (es) *	2011-07-12	2016-10-17	Astrazeneca Ab	N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.

2012
- 2012-07-10 MX MX2013015085A patent/MX342874B/es active IP Right Grant
- 2012-07-10 PH PH1/2014/500107A patent/PH12014500107A1/en unknown
- 2012-07-10 PL PL16202983T patent/PL3255043T3/pl unknown
- 2012-07-10 LT LTEP16202983.9T patent/LT3255043T/lt unknown
- 2012-07-10 PE PE2018000520A patent/PE20181069A1/es unknown
- 2012-07-10 ES ES16202983T patent/ES2861927T3/es active Active
- 2012-07-10 HU HUE16202983A patent/HUE053703T2/hu unknown
- 2012-07-10 CA CA2841859A patent/CA2841859C/en active Active
- 2012-07-10 DK DK16202983.9T patent/DK3255043T3/da active
- 2012-07-10 PT PT162029839T patent/PT3255043T/pt unknown
- 2012-07-10 SM SM20210173T patent/SMT202100173T1/it unknown
- 2012-07-10 MY MYPI2014700061A patent/MY180039A/en unknown
- 2012-07-10 EP EP12735323.3A patent/EP2731945A1/en not_active Withdrawn
- 2012-07-10 KR KR1020147000487A patent/KR101946664B1/ko not_active Expired - Fee Related
- 2012-07-10 JP JP2014519625A patent/JP6006308B2/ja not_active Expired - Fee Related
- 2012-07-10 EA EA201490077A patent/EA027821B1/ru not_active IP Right Cessation
- 2012-07-10 SG SG10201605619XA patent/SG10201605619XA/en unknown
- 2012-07-10 CU CUP2014000004A patent/CU24292B1/es unknown
- 2012-07-10 CN CN201280044385.0A patent/CN103781781B/zh not_active Expired - Fee Related
- 2012-07-10 PE PE2014000009A patent/PE20141944A1/es active IP Right Grant
- 2012-07-10 BR BR112014000636-9A patent/BR112014000636B1/pt not_active IP Right Cessation
- 2012-07-10 WO PCT/GB2012/051620 patent/WO2013008002A1/en not_active Ceased
- 2012-07-10 SI SI201231899T patent/SI3255043T1/sl unknown
- 2012-07-10 MX MX2016000277A patent/MX353334B/es unknown
- 2012-07-10 EP EP16202983.9A patent/EP3255043B1/en active Active
- 2012-07-10 RS RS20210370A patent/RS61608B1/sr unknown
- 2012-07-10 AU AU2012282316A patent/AU2012282316B2/en not_active Ceased
- 2012-07-11 US US13/546,444 patent/US8735413B2/en active Active
- 2012-07-11 TW TW101124908A patent/TWI633098B/zh not_active IP Right Cessation
- 2012-07-11 TW TW106135796A patent/TWI659026B/zh not_active IP Right Cessation
- 2012-07-11 UY UY0001034191A patent/UY34191A/es not_active Application Discontinuation
- 2012-07-12 AR ARP120102531A patent/AR087168A1/es not_active Application Discontinuation
2013
- 2013-12-17 DO DO2013000308A patent/DOP2013000308A/es unknown
2014
- 2014-01-09 CR CR20140007A patent/CR20140007A/es unknown
- 2014-01-09 NI NI201400002A patent/NI201400002A/es unknown
- 2014-01-09 IL IL230398A patent/IL230398A/en active IP Right Grant
- 2014-01-10 EC ECSP14013130 patent/ECSP14013130A/es unknown
- 2014-01-10 CL CL2014000079A patent/CL2014000079A1/es unknown
- 2014-01-10 CO CO14004182A patent/CO6852072A2/es active IP Right Grant
- 2014-02-11 ZA ZA2014/01059A patent/ZA201401059B/en unknown
- 2014-04-15 US US14/253,288 patent/US9221782B2/en not_active Expired - Fee Related
2015
- 2015-12-28 US US14/980,754 patent/US9975881B2/en active Active
2016
- 2016-06-10 CU CUP2016000083A patent/CU20160083A7/es unknown
- 2016-07-01 JP JP2016131785A patent/JP6261666B2/ja not_active Expired - Fee Related
- 2016-10-12 AU AU2016244246A patent/AU2016244246B2/en not_active Ceased
2021
- 2021-03-12 HR HRP20210413TT patent/HRP20210413T1/hr unknown
- 2021-04-07 CY CY20211100296T patent/CY1124329T1/el unknown
2022
- 2022-01-21 AR ARP220100128A patent/AR124688A2/es unknown

Also Published As

Publication number	Publication date
CU24292B1 (es)	2017-12-08
CN103781781A (zh)	2014-05-07
CO6852072A2 (es)	2014-01-30
CR20140007A (es)	2014-05-14
ES2861927T3 (es)	2021-10-06
SMT202100173T1 (it)	2021-05-07
JP2014520838A (ja)	2014-08-25
JP6006308B2 (ja)	2016-10-12
PE20141944A1 (es)	2014-12-24
EP3255043A2 (en)	2017-12-13
NI201400002A (es)	2016-02-16
BR112014000636A2 (pt)	2017-01-10
MX2013015085A (es)	2014-01-24
DK3255043T3 (da)	2021-03-29
NZ619001A (en)	2016-05-27
PT3255043T (pt)	2021-03-29
PE20181069A1 (es)	2018-07-04
AR087168A1 (es)	2014-02-26
US8735413B2 (en)	2014-05-27
AU2012282316B2 (en)	2016-07-14
TW201311670A (zh)	2013-03-16
CN103781781B (zh)	2015-08-26
TWI659026B (zh)	2019-05-11
SG10201605619XA (en)	2016-08-30
HUE053703T2 (hu)	2021-07-28
WO2013008002A1 (en)	2013-01-17
CU20160083A7 (es)	2017-03-03
TW201825479A (zh)	2018-07-16
RS61608B1 (sr)	2021-04-29
US9221782B2 (en)	2015-12-29
CA2841859C (en)	2021-03-09
MY180039A (en)	2020-11-20
HK1245779A1 (en)	2018-08-31
AU2016244246B2 (en)	2017-11-23
PL3255043T3 (pl)	2021-07-12
CY1124329T1 (el)	2022-07-22
US9975881B2 (en)	2018-05-22
EP3255043A3 (en)	2018-04-18
DOP2013000308A (es)	2014-02-28
TWI633098B (zh)	2018-08-21
AU2012282316A1 (en)	2013-05-02
UY34191A (es)	2013-02-28
MX342874B (es)	2016-10-17
AU2016244246A1 (en)	2016-10-27
EP2731945A1 (en)	2014-05-21
CA2841859A1 (en)	2013-01-17
JP2016190864A (ja)	2016-11-10
EP3255043B1 (en)	2021-01-20
EA201490077A1 (ru)	2014-10-30
SI3255043T1 (sl)	2021-04-30
KR101946664B1 (ko)	2019-02-11
LT3255043T (lt)	2021-04-12
ECSP14013130A (es)	2014-02-28
IL230398A (en)	2017-10-31
KR20140037915A (ko)	2014-03-27
CU20140004A7 (es)	2014-05-27
NZ719176A (en)	2017-11-24
MX353334B (es)	2018-01-09
HRP20210413T1 (hr)	2021-05-14
US20140228339A1 (en)	2014-08-14
PH12014500107A1 (en)	2014-03-03
US20130040926A1 (en)	2013-02-14
AR124688A2 (es)	2023-04-26
BR112014000636B1 (pt)	2022-08-30
EA027821B1 (ru)	2017-09-29
US20160108023A1 (en)	2016-04-21
JP6261666B2 (ja)	2018-01-17
ZA201401059B (en)	2017-09-27

Publication	Publication Date	Title
CL2014000079A1 (es)	2014-06-27	El compuesto n-(6-((2r,3s)-3,4-dihidroxibutan-2iloxi)-2-(4-fluorobenciltio) pirimidin-4-ilo)-3-metilacetidina-1-sulfonamida, receptor de qumiocina; forma cristalina; proceso de preparación; compuesto intermediario; composicion farmaceutica; y su uso en asma, rinitis alergica, epoc, sindrome de colon irritable, enfermedad intestinal inflamatoria, entre otras
CL2013003333A1 (es)	2015-02-27	Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
IL269858A (en)	2019-11-28	Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
CL2008000307A1 (es)	2008-05-30	Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
CL2013000261A1 (es)	2013-11-04	Compuestos derivados de heterociclos nitrogenados, con actividad ampk; composicion farmaceutica; metodos in vitro; y su uso en enfermedades cardiovasculares, diabetes tipo ii, distrofia muscular, trastornos neurolgicos, enfermedades inflamatorias, entre otras.
DK2140867T4 (da)	2023-09-25	Farmaceutisk sammensætning
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
BRPI0813680A2 (pt)	2015-01-06	AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
SMT201600164B (it)	2016-07-01	Nuove n-acil-5, 6, 7, ( 8-s0stituito )-tetraidro-[1, 2, 4]triazolo[4, 3-a]pirazine chirali come antagonisti selettivi del recettore nk-3, composizione farmaceutica, e metodi per l'uso in disturbi mediati dal recettore nk-3
SMT201700095B (is)	2017-03-08	Composizioni farmaceutiche per inalazione
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
IL214425A (en)	2015-07-30	Converted metastatic heterocyclic compounds, their pharmaceutical preparations and their uses
CL2008001818A1 (es)	2009-03-06	Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
RU2493831C3 (ru)	2017-06-08	Фармацевтические композиции
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
BRPI0809346A2 (pt)	2014-10-07	Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
BR112014013332A2 (pt)	2017-06-13	composições farmacêutica de 7-(6-(2-hidroxi-propan-2-il)-1-((trans)-4-metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
CL2013001591A1 (es)	2013-12-27	Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
BRPI0915427A2 (pt)	2015-11-03	composição farmacêutica